Investor Presentaiton
Revenue Tops 5.39B RMB with Net Profit of 546M RMB
Revenue
BD
៣
ເຮົາ Pipeline
Commercial
Capacity
5.39B RMB
Commercialization
4
BD
Achieved sustainable and
profitable growth from strong
sales team & effective sales
management
Over RMB 100M average
monthly sales in China from
HLX10 (Serplulimab, PD-1)
since March 2023; approval
of new indication ESCC
HLX02 (trastuzumab)
average monthly sales in
China exceeding RMB 200M
since Q2 2023 with a lower
expense ratio
.
HLX10 out-licensed to Intas in
Europe 50+ countries and
India, with upfront payment up
to EUR 42M1, a total payment
up to EUR 185M
HLX10 out-licensed to Kalbe
in the MENA, with upfront
payment of USD 7M and a
total amount up to USD 665M²
In-licensed exclusive rights of
Lasofoxifene (SERM) in China
from Sermonix for HR+/HER2-
breast cancer
50+
R&D
The clinical data of HLX10 for
1L sqNSCLC phase III
(ASTRUM-004) was presented
in WCLC
HLX10+ chemo combo
approved for 1L ESCC in China
HLX42 (EGFR ADC) for TKI
failed NSCLC was granted
FDA Fast Track Destination
(FTD) and entered into phase I
HLX43 (PD-L1 ADC), a
potential first-in-class product,
entered into phase I
•
48KL
Manufacturing
Xuhui Site and Songjiang 1st
Plant have passed EU GMP
inspection of production
areas for HLX10
Xuhui Site passed
Indonesia's BPOM (PIC/S
member country) inspection
of HLX10 production lines
Xuhui Site passed Brazil's
ANVISA (PIC/S) GMP
compliance inspection for
HLX01 and HLX02
Operating
Cash Flow
1.05B RMB
1. The first part of upfront payment EUR 26M will be paid upon on agreement effective date; and the second part of the upfront payment EUR 16M will be paid when the EMA issues positive
3 opinion (210th day of the evaluation procedure) on the 1L treatment for ES-SCLC; 2. The scope of the sales milestone payments will also include the previously authorized Southeast Asia region,
and the total sales milestone payments for the two authorizations will be no more than US$650M
•
·
Financial
Total revenue reached RMB
5.39B in 2023, 67.8% YoY
growth
Total product sales reached
RMB 4.55B, 70.2% YoY
growth
Net operating cash inflow of
RMB 1.05B
Net profit reached RMB
546M, and net profit rate was
10.1%
2 HenliusView entire presentation